Folgen
Felix A Krüger
Felix A Krüger
ML Engineer
Bestätigte E-Mail-Adresse bei posteo.eu
Titel
Zitiert von
Zitiert von
Jahr
The ChEMBL bioactivity database: an update
AP Bento, A Gaulton, A Hersey, LJ Bellis, J Chambers, M Davies, ...
Nucleic acids research 42 (D1), D1083-D1090, 2014
16012014
The druggable genome and support for target identification and validation in drug development
C Finan, A Gaulton, FA Kruger, RT Lumbers, T Shah, J Engmann, ...
Science translational medicine 9 (383), eaag1166, 2017
4772017
Improving the odds of drug development success through human genomics: modelling study
AD Hingorani, V Kuan, C Finan, FA Kruger, A Gaulton, S Chopade, ...
Scientific reports 9 (1), 18911, 2019
1732019
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis
J White, R Sofat, G Hemani, T Shah, J Engmann, C Dale, S Shah, ...
The lancet Diabetes & endocrinology 4 (4), 327-336, 2016
1422016
Global analysis of small molecule binding to related protein targets
FA Kruger, JP Overington
PLoS computational biology 8 (1), e1002333, 2012
512012
Structural and functional view of polypharmacology
A Moya-García, T Adeyelu, FA Kruger, NL Dawson, JG Lees, ...
Scientific reports 7 (1), 10102, 2017
442017
Collation and data-mining of literature bioactivity data for drug discovery
LJ Bellis, R Akhtar, B Al-Lazikani, F Atkinson, AP Bento, J Chambers, ...
Biochemical Society Transactions 39 (5), 1365-1370, 2011
442011
Mapping small molecule binding data to structural domains
FA Kruger, R Rostom, JP Overington
BMC bioinformatics 13, 1-13, 2012
282012
Classification and regression by randomForest
AP Bento, A Gaulton, A Hersey, LJ Bellis, J Chambers, M Davies, ...
R News 23 (23), 2002
212002
PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains
FA Kruger, A Gaulton, M Nowotka, JP Overington
Bioinformatics 31 (5), 776-778, 2015
112015
UCLEB (University College London-London School of Hygiene & Tropical Medicine-Edinburgh-Bristol Consortium. Plasma urate concentration and risk of coronary heart disease: a …
J White, R Sofat, G Hemani, T Shah, J Engmann, C Dale, S Shah, ...
Lancet Diabetes Endocrinol 4 (4), 327-336, 2016
92016
The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017; 9 (383)
C Finan, A Gaulton, FA Kruger, RT Lumbers, T Shah, J Engmann
Epub 2017/03/31. https://doi. org/10.1126/scitranslmed. aag1166 PMID: 28356508, 0
9
The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017; 9: eaag1166
C Finan, A Gaulton, FA Kruger, RT Lumbers, T Shah, J Engmann
9
The druggable genome and support for target identification and validation in drug development. Sci Transl Med
C Finan, A Gaulton, FA Kruger, RT Lumbers, T Shah, J Engmann, ...
82017
Fragment formal concept analysis accurately classifies compounds with closely related biological activities
F Krüger, E Lounkine, J Bajorath
ChemMedChem: Chemistry Enabling Drug Discovery 4 (7), 1174-1181, 2009
62009
International Consortium for Blood P, Smith GD, Dudbridge F, Casas JP, Holmes MV, Hingorani AD and Ucleb. Plasma urate concentration and risk of coronary heart disease: a …
J White, R Sofat, G Hemani, T Shah, J Engmann, C Dale, S Shah, ...
The lancet Diabetes & endocrinology 4, 327-36, 2016
42016
ChEMBL-linking chemistry and biology to enable mapping onto molecular pathways
LJ Bellis, A Gaulton, A Hersey, AP Bento, J Chambers, M Davies, ...
Papers of the American Chemical Society 248, 2014
12014
Flipping the odds of drug development success through human genomics
AD Hingorani, V Kuan, C Finan, FA Kruger, A Gaulton, S Chopade, ...
bioRxiv, 170142, 2017
2017
Structural and Functional View of Polypharmacology
T Adeyelu, FA Kruger, NL Dawson, JG Lees, JP Overington, C Orengo, ...
2016
Integration and analysis of protein evolutionary relationships and small molecule bioactivity data
F Krüger
2014
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20